Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Actuarial Approach01:20

Actuarial Approach

284
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
284
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

548
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Invasive urothelial carcinoma in association with surface low-grade papillary urothelial carcinoma: clinical and pathologic insights from a rare entity.

American journal of clinical pathology·2026
Same author

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

JCO clinical cancer informatics·2026
Same author

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Polygenic risk scores for prediction of immune checkpoint inhibitor thyroid toxicity in diverse populations.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Patient-reported duplication and missed breast cancer survivorship care more than 5 years after initial treatment.

Journal of cancer survivorship : research and practice·2026
Same journal

The Role of Telemedicine on Interhospital Transfer Outcomes : A Systematic Review.

Annals of internal medicine·2026
Same journal

Prolonged Short Sleep and Its Effect on Body Weight and Composition : A Pooled Analysis of Randomized Trials.

Annals of internal medicine·2026
Same journal

In AF, LAAC was noninferior to NOAC therapy for a composite efficacy outcome and reduced non-procedure-related bleeding at 3 y.

Annals of internal medicine·2026
Same journal

How AI is affecting medical journals.

Annals of internal medicine·2026
Same journal

In adults with COPD, the BLISS score predicted risk for acute respiratory hospital admission at 2 y.

Annals of internal medicine·2026
Same journal

In AF at risk for stroke and bleeding, LAAC was not noninferior to medical therapy for a composite of thromboembolic and safety events.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

637

Predicting Long-Term Risk for Prostate Cancer Mortality Following a Prostate-Specific Antigen Screening Test:

Patrick Lewicki1, Ralph Jiang2, Archana Radhakrishnan3

  • 1Department of Urology, University of Michigan, Ann Arbor, Michigan (P.L., T.M.M.).

Annals of Internal Medicine
|January 12, 2026
PubMed
Summary
This summary is machine-generated.

A new prostate cancer mortality risk model was developed and validated. This model improves the interpretation of prostate-specific antigen (PSA) test results for predicting prostate cancer-specific mortality (PCSM).

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.3K

Related Experiment Videos

Last Updated: Jan 14, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

637
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.3K

Area of Science:

  • Urology
  • Oncology
  • Biostatistics
  • Public Health

Background:

  • Current prostate cancer (PCa) screening using prostate-specific antigen (PSA) testing lacks models that predict time-to-event outcomes or account for patient life expectancy.
  • Existing prediction models for PCa do not adequately address the nuances of mortality risk over time.

Purpose of the Study:

  • To develop a novel prognostic model for predicting prostate cancer-specific mortality (PCSM) risk following a PSA test.
  • To externally validate this new model and compare its performance against existing risk prediction tools.
  • To enhance the interpretation of PSA test results in the context of long-term mortality risk.

Main Methods:

  • Prognostic model development utilized data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial PCa screening group.
  • External validation was performed on a large Veterans Affairs (VA) cohort of patients who underwent PSA testing.
  • Key predictors included PSA level, family history of PCa, race, age, BMI, smoking status, and comorbidities (hypertension, diabetes, stroke).

Main Results:

  • The novel model demonstrated superior performance compared to a previously validated prostate biopsy risk model (PBCG) in both development and validation cohorts.
  • In the development cohort, the area under the receiver operating characteristic curve (AUC) at 29.5 years was 0.666 for the new model versus 0.643 for PBCG (P < 0.001).
  • In the external validation cohort, the AUC at 20 years was 0.776 for the new model compared to 0.749 for PBCG (P = 0.031).

Conclusions:

  • A new prognostic model for PCSM has been successfully developed and validated using long-term clinical trial and national cohort data.
  • This model offers improved accuracy in predicting PCa-specific mortality risk compared to existing tools.
  • The validated model can aid clinicians in better interpreting PSA test results and assessing individual patient risk.